Skip to main content
Signal8

Perspective Therapeutics, Inc. (CATX)

Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.

Sector: Pharmaceutical Preparations

Industry: Medical - Devices

Perspective Therapeutics, Inc. logo

Perspective Therapeutics, Inc.

NYSE:CATXHealthcare
-24.84%$1.21
AH Close$1.19-1.65%vs close
Mkt Cap$138.12M
Float95.07M
O/S114.15M
Inst Own76.4%
SI17.6%
Dilution
Perspective Therapeutics, Inc. logoNYSE:CATX$1.21-24.84%
FormDescription
8-K
8.01,9.01
4
8-K
8.01,9.01
2
8-K
8.01,9.01
13D/A
8-K
8.01,9.01
3
8-K
8.01,9.01
1
4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
13D/A
4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
13G/A
Beneficial Ownership Report (Amended)
10-Q
8-K
13G
Beneficial Ownership Report
8-K
8.01,9.01
13G
Beneficial Ownership Report
13G
Beneficial Ownership Report
8-K
8.01,9.01
13G
Beneficial Ownership Report
8-K
8.01,9.01
8-K
5.07
2
8-K
8.01,9.01
3
13G/A
Beneficial Ownership Report (Amended)

1-25 of 1,141

…